Baker Julian 的 Form 4 申報
Madrigal Pharmaceuticals, Inc.（MDGL），2025/8/20 申報
- 申報編號
- 0000950170-25-110502
- 申報時間
- 2025/8/20 18:12 ET
- 交易日
- 2025/8/18-8/20
- 申報延遲
- 2 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 26 筆非衍生性交易。公開市場買進合計 $3,694 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Baker JulianCIK 0001087939 | 董事 |
| Baker FelixCIK 0001087940 | 董事 |
| Baker Bros. Advisors LPCIK 0001263508 | 董事 |
| Baker Brothers Life Sciences LPCIK 0001363364 | 董事 |
| 667, L.P.CIK 0001551139 | 董事 |
| Baker Bros. Advisors (GP) LLCCIK 0001580575 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/8/18 | Common Stock | P買進取得 | +2,460 | $372.87F1 | +$917,258.48 | 197,085 | 間接 | |
| 2025/8/18 | Common Stock | P買進取得 | +26,704 | $372.87F1 | +$9,957,101.79 | 1,885,795 | 間接 | |
| 2025/8/18 | Common Stock | P買進取得 | +675 | $374.43F15 | +$252,742.82 | 197,760 | 間接 | |
| 2025/8/18 | Common Stock | P買進取得 | +7,325 | $374.43F15 | +$2,742,727.59 | 1,893,120 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +480 | $380.44F9 | +$182,609.52 | 198,240 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +5,209 | $380.44F9 | +$1,981,693.73 | 1,898,329 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +176 | $380.78 | +$67,017.28 | 198,416 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +1,919 | $380.78 | +$730,716.82 | 1,900,248 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +873 | $381.12F10 | +$332,719.16 | 199,289 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +9,477 | $381.12F10 | +$3,611,889.4 | 1,909,725 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +105 | $382.29F11 | +$40,140.36 | 199,394 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +1,136 | $382.29F11 | +$434,280.42 | 1,910,861 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +262 | $382.82F12 | +$100,299.18 | 199,656 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +2,838 | $382.82F12 | +$1,086,446.85 | 1,913,699 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +373 | $383.79F13 | +$143,152.63 | 200,029 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +4,049 | $383.79F13 | +$1,553,954.37 | 1,917,748 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +1,248 | $385.06F14 | +$480,551.51 | 201,277 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +13,545 | $385.06F14 | +$5,215,601.13 | 1,931,293 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +409 | $387.07F16 | +$158,310.81 | 201,686 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +4,441 | $387.07F16 | +$1,718,968.99 | 1,935,734 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +34 | $389.00 | +$13,226 | 201,720 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +366 | $389.00 | +$142,374 | 1,936,100 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +231 | $389.89F17 | +$90,064.08 | 201,951 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +2,506 | $389.89F17 | +$977,058.83 | 1,938,606 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +862 | $392.24F18 | +$338,113.38 | 202,813 | 間接 | |
| 2025/8/20 | Common Stock | P買進取得 | +9,362 | $392.24F18 | +$3,672,178.03 | 1,947,968 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $372.59 to $373.54, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F9
The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $380.03 to $380.84, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F10
The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $380.98 to $381.94, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F11
The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $382.00 to $382.36, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F12
The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $382.20 to $383.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F13
The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $383.42 to $384.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F14
The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $385.00 to $385.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F15
The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $374.09 to $374.67, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F16
The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $387.00 to $387.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F17
The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $389.44 to $390.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
- F18
The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $391.69 to $392.57, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
表 I 有 2 筆交易的價格引用這則附註。
備註
Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC, and Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP, are directors of Madrigal Pharmaceuticals, Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Julian C. Baker are deemed directors by deputization of the Issuer. This is the second of two Form 4's reporting changes in beneficial ownership. Due to space limitations in Form 4 we are thus filing these two Forms 4.